Talix Therapeutics

Focus: R&D of immune based cancer therapies

Lead Program: Co-stimulatory anti CD96 monoclonal antibody

Development Stage: Late stage discovery – lead candidate & backup identified, ex vivo validation in head & neck tumor TILs

Potential indications:

1. T cell infiltrated solid tumors such as head & neck, lung, breast, endometrium, cervical cancer, CRC, melanoma …
2. Adjuvant for active immunotherapies (cell based, peptide, DNA, RNA vaccines…)

Treatment approach

1. Monotherapy opportunity
2. Combination therapy with checkpoint inhibitors

Unique approach: Leader in targeting CD96 as a breakthrough, first-in-class co-stimulatory agent in immuno-oncology

IP: Broad IP portfolio covering composition of matter  as well as target mechanism of action with protection until 2037

Investment sought: 15 M€ series A to advance the lead program to first-in-man clinical trial